UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Euthyroid hyperthyroxinemia and hypothyroxinemia

Author
Douglas S Ross, MD
Section Editor
David S Cooper, MD
Deputy Editor
Jean E Mulder, MD

INTRODUCTION

Many conditions result in increases or decreases in serum total thyroxine (T4) and triiodothyronine (T3) concentrations, associated with normal thyroid-stimulating hormone (TSH) concentrations and no symptoms or signs of thyroid dysfunction. This constellation of laboratory values has been referred to as euthyroid hyperthyroxinemia and hypothyroxinemia, respectively. The free T4 should be normal, but many assays will report slightly abnormal values, for example the free T4 index and many direct free T4 assays report high values in familial dysalbuminemic hyperthyroxinemia.

In the past, these conditions presented a diagnostic challenge, and many of the patients with them were inappropriately treated for thyroid disease. Today, when most clinicians measure serum TSH as a screening test for thyroid function, a normal serum TSH value is usually not followed by measurement of a total serum T4. With the use of sensitive serum TSH assays and automated “direct” free T4 assays, euthyroid hyper- or hypothyroxinemia frequently remains undetected, with no harm to the patient.

However, the detection of a normal serum TSH concentration associated with a high or low serum T4 concentration, and sometimes free T4 concentration, should immediately alert the clinician to search for one of the causes of euthyroid hyperthyroxinemia or hypothyroxinemia, especially if the patient has no symptoms or signs of either hyper- or hypothyroidism.

This topic will review these conditions. Individual thyroid function tests are discussed in detail separately. (See "Laboratory assessment of thyroid function".)

EUTHYROID HYPERTHYROXINEMIA DUE TO BINDING PROTEIN ABNORMALITIES

Both thyroxine (T4) and triiodothyronine (T3) circulate in blood bound to one of three binding proteins:

                

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Fri Feb 26 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Refetoff S. Inherited thyroxine-binding globulin abnormalities in man. Endocr Rev 1989; 10:275.
  2. Ain KB, Refetoff S. Relationship of oligosaccharide modification to the cause of serum thyroxine-binding globulin excess. J Clin Endocrinol Metab 1988; 66:1037.
  3. DOWLING JT, FREINKEL N, INGBAR SH. Thyroxine-binding by sera of pregnant women, newborn infants, and women with spontaneous abortion. J Clin Invest 1956; 35:1263.
  4. Swanson MA, Custer TR, Suey CM. Free thyroxine and free thyroxine index in women taking oral contraceptives. Clin Nucl Med 1981; 6:168.
  5. Steingold KA, Matt DW, DeZiegler D, et al. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. J Clin Endocrinol Metab 1991; 73:275.
  6. Mamby CC, Love RR, Lee KE. Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J Clin Oncol 1995; 13:854.
  7. Duntas LH, Mantzou E, Koutras DA. Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status. Thyroid 2001; 11:779.
  8. Schussler GC, Schaffner F, Korn F. Increased serum thyroid hormone binding and decreased free hormone in chronic active liver disease. N Engl J Med 1978; 299:510.
  9. Ross DS, Daniels GH, Dienstag JL, Ridgway EC. Elevated thyroxine levels due to increased thyroxine-binding globulin in acute hepatitis. Am J Med 1983; 74:564.
  10. Beex LV, Ross A, Smals AG, Kloppenborg PW. Letter: 5-fluorouracil and the thyroid. Lancet 1976; 1:866.
  11. McKerron CG, Scott RL, Asper SP, Levy RI. Effects of clofibrate (Atromid S) on the thyroxine-binding capacity of thyroxine-binding globulin and free thyroxine. J Clin Endocrinol Metab 1969; 29:957.
  12. Azizi F, Vagenakis AG, Portnay GI, et al. Thyroxine transport and metabolism in methadone and heroin addicts. Ann Intern Med 1974; 80:194.
  13. Hollander CS, Scott RL, Tschudy DP, et al. Increased protein-bound iodine and thyroxine-binding globulin in acute intermittent porphyria. N Engl J Med 1967; 277:995.
  14. Lee RH, Spencer CA, Mestman JH, et al. Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol 2009; 200:260.e1.
  15. Arevalo G. Prevalence of familial dysalbuminemic hyperthyroxinemia in serum samples received for thyroid testing. Clin Chem 1991; 37:1430.
  16. Ruiz M, Rajatanavin R, Young RA, et al. Familial dysalbuminemic hyperthyroxinemia: a syndrome that can be confused with thyrotoxicosis. N Engl J Med 1982; 306:635.
  17. Cartwright D, O'Shea P, Rajanayagam O, et al. Familial dysalbuminemic hyperthyroxinemia: a persistent diagnostic challenge. Clin Chem 2009; 55:1044.
  18. Wada N, Chiba H, Shimizu C, et al. A novel missense mutation in codon 218 of the albumin gene in a distinct phenotype of familial dysalbuminemic hyperthyroxinemia in a Japanese kindred. J Clin Endocrinol Metab 1997; 82:3246.
  19. Sunthornthepvarakul T, Likitmaskul S, Ngowngarmratana S, et al. Familial dysalbuminemic hypertriiodothyroninemia: a new, dominantly inherited albumin defect. J Clin Endocrinol Metab 1998; 83:1448.
  20. Moses AC, Lawlor J, Haddow J, Jackson IM. Familial euthyroid hyperthyroxinemia resulting from increased thyroxine binding to thyroxine-binding prealbumin. N Engl J Med 1982; 306:966.
  21. Stockigt JR, Dyer SA, Mohr VS, et al. Specific methods to identify plasma binding abnormalities in euthyroid hyperthyroxinemia. J Clin Endocrinol Metab 1986; 62:230.
  22. John R, Henley R, Shankland D. Concentrations of free thyroxin and free triiodothyronine in serum of patients with thyroxin- and triiodothyronine-binding autoantibodies. Clin Chem 1990; 36:470.
  23. Hisaoka T, Iino S, Saitoh H, et al. [Studies on patients with a discrepancy between free thyroid hormones and thyrotropin values]. Nihon Naibunpi Gakkai Zasshi 1994; 70:563.
  24. Figge HL, Figge J. The effects of amiodarone on thyroid hormone function: a review of the physiology and clinical manifestations. J Clin Pharmacol 1990; 30:588.
  25. Cooper DS, Daniels GH, Ladenson PW, Ridgway EC. Hyperthyroxinemia in patients treated with high-dose propranolol. Am J Med 1982; 73:867.
  26. Wu SY, Chopra IJ, Solomon DH, Bennett LR. Changes in circulating iodothyronines in euthyroid and hyperthyroid subjects given ipodate (Oragrafin), an agent for oral cholecystography. J Clin Endocrinol Metab 1978; 46:691.
  27. Suzuki H, Noguchi K, Nakahata M, et al. Effect of Iopanoic acid on the pituitary-thyroid axis: time sequence of changes in serum iodothyronines, thyrotropin, and prolactin concentrations and responses to thyroid hormones. J Clin Endocrinol Metab 1981; 53:779.
  28. Kwok JS, Chan IH, Chan MH. Biotin interference on TSH and free thyroid hormone measurement. Pathology 2012; 44:278.
  29. Spratt DI, Pont A, Miller MB, et al. Hyperthyroxinemia in patients with acute psychiatric disorders. Am J Med 1982; 73:41.
  30. Gavin LA, Rosenthal M, Cavalieri RR. The diagnostic dilemma of isolated hyperthyroxinemia in acute illness. JAMA 1979; 242:251.
  31. Styra R, Joffe R, Singer W. Hyperthyroxinemia in major affective disorders. Acta Psychiatr Scand 1991; 83:61.
  32. Mordes JP, Blume FD, Boyer S, et al. High-altitude pituitary-thyroid dysfunction on Mount Everest. N Engl J Med 1983; 308:1135.
  33. Morley JE, Shafer RB, Elson MK, et al. Amphetamine-induced hyperthyroxinemia. Ann Intern Med 1980; 93:707.
  34. Cogan E, Abramow M. Transient hyperthyroxinemia in symptomatic hyponatremic patients. Arch Intern Med 1986; 146:545.
  35. Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987; 316:764.
  36. Inagaki A, Miura Y, Mori Y, et al. Gene screening of thyroxine-binding globulin (TBG) deficiencies in the Japanese: only two mutations account for TBG deficiencies in the Japanese. J Clin Endocrinol Metab 1996; 81:580.
  37. Ueta Y, Mitani Y, Yoshida A, et al. A novel mutation causing complete deficiency of thyroxine binding globulin. Clin Endocrinol (Oxf) 1997; 47:1.
  38. Kobayashi H, Sakurai A, Katai M, Hashizume K. Autosomally transmitted low concentration of thyroxine-binding globulin. Thyroid 1999; 9:159.
  39. Arafah BM. Decreased levothyroxine requirement in women with hypothyroidism during androgen therapy for breast cancer. Ann Intern Med 1994; 121:247.
  40. Oppenheimer JH, Werner SC. Effect of prednisone on thyroxine-binding proteins. J Clin Endocrinol Metab 1966; 26:715.
  41. Kaplan MM. Clinical and laboratory assessment of thyroid abnormalities. Med Clin North Am 1985; 69:863.
  42. Feinstein EI, Kaptein EM, Nicoloff JT, Massry SG. Thyroid function in patients with nephrotic syndrome and normal renal function. Am J Nephrol 1982; 2:70.
  43. Garnick MB, Larsen PR. Acute deficiency of thyroxine-binding globulin during L-asparaginase therapy. N Engl J Med 1979; 301:252.
  44. Graham RL, Gambrell RD Jr. Changes in thyroid function tests during danazol therapy. Obstet Gynecol 1980; 55:395.
  45. Shakir KM, Kroll S, Aprill BS, et al. Nicotinic acid decreases serum thyroid hormone levels while maintaining a euthyroid state. Mayo Clin Proc 1995; 70:556.
  46. Faber J, Waetjen I, Siersbaek-Nielsen K. Free thyroxine measured in undiluted serum by dialysis and ultrafiltration: effects of non-thyroidal illness, and an acute load of salicylate or heparin. Clin Chim Acta 1993; 223:159.
  47. McConnell RJ. Abnormal thyroid function test results in patients taking salsalate. JAMA 1992; 267:1242.
  48. Stockigt JR, Lim CF, Barlow JW, et al. Interaction of furosemide with serum thyroxine-binding sites: in vivo and in vitro studies and comparison with other inhibitors. J Clin Endocrinol Metab 1985; 60:1025.
  49. Mendel CM, Frost PH, Kunitake ST, Cavalieri RR. Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. J Clin Endocrinol Metab 1987; 65:1259.
  50. Smith PJ, Surks MI. Multiple effects of 5,5'-diphenylhydantoin on the thyroid hormone system. Endocr Rev 1984; 5:514.
  51. Isojärvi JI, Pakarinen AJ, Myllylä VV. Thyroid function in epileptic patients treated with carbamazepine. Arch Neurol 1989; 46:1175.
  52. Surks MI, DeFesi CR. Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine. A paradox resolved. JAMA 1996; 275:1495.
  53. Isojärvi JI, Turkka J, Pakarinen AJ, et al. Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia 2001; 42:930.
  54. Blackshear JL, Schultz AL, Napier JS, Stuart DD. Thyroxine replacement requirements in hypothyroid patients receiving phenytoin. Ann Intern Med 1983; 99:341.
  55. Jackson IM. Does thyroid hormone have a role as adjunctive therapy in depression? Thyroid 1996; 6:63.